INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.41 USD | -1.05% |
|
+1.94% | -6.98% |
| May. 23 | Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target | MT |
| May. 21 | Incyte Acquires 2 Office Buildings in Delaware | MT |
Financials (USD)
| Sales 2024 * | 4.09B | Sales 2025 * | 4.52B | Capitalization | 13.13B |
|---|---|---|---|---|---|
| Net income 2024 * | 759M | Net income 2025 * | 963M | EV / Sales 2024 * | 2.28 x |
| Net cash position 2024 * | 3.83B | Net cash position 2025 * | 5.41B | EV / Sales 2025 * | 1.71 x |
| P/E ratio 2024 * |
18
x | P/E ratio 2025 * |
14.5
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | -1.05% | ||
| 1 week | +1.94% | ||
| Current month | +1.07% | ||
| 1 month | +8.01% | ||
| 3 months | -1.43% | ||
| 6 months | +5.40% | ||
| Current year | -6.98% |
1 week
57.56
59.32
1 month
52.8159.32
Current year
50.3567.37
1 year
50.2767.37
3 years
50.2788.26
5 years
50.27110.37
10 years
43.86153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 14-01-12 |
| Director of Finance/CFO | 53 | 19-02-10 | |
Steven Stein
CTO | Chief Tech/Sci/R&D Officer | 57 | 15-03-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 00-12-31 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 19-12-15 |
| Director/Board Member | 70 | 15-01-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 254 M€ | +12.74% | - | |
| 2.94% | 1 M€ | +0.84% | - | |
| 2.88% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 58.41 | -1.05% | 7,860,251 |
| 24-06-05 | 59.03 | +0.79% | 7,494,737 |
| 24-06-04 | 58.57 | -0.39% | 6,497,868 |
| 24-06-03 | 58.8 | +1.75% | 7,764,689 |
| 24-05-31 | 57.79 | +0.86% | 5,049,814 |
Delayed Quote Nasdaq, June 06, 2024 at 04:00 pm EDT
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-06-10
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
58.41
USD
Average target price
72.8
USD
Spread / Average Target
+24.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.98% | 13.13B | |
| +0.82% | 93.19B | |
| 0.00% | 39.62B | |
| -10.35% | 33.78B | |
| +65.15% | 26.82B | |
| -16.15% | 15.35B | |
| -11.77% | 11.6B | |
| -49.19% | 10.26B | |
| +5.69% | 9.43B | |
| +141.62% | 9.26B |
- Stock Market
- Equities
- INCY Stock
